• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Acadia Pharmaceuticals Set to Join S&P SmallCap 600

    12/30/24 5:37:00 PM ET
    $ACAD
    $IBTX
    $SPGI
    $SSB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Banks
    Finance
    Get the next $ACAD alert in real time by email

    NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

    Following is a summary of the change that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    Jan 3, 2025

    S&P SmallCap 600

    Addition

    Acadia Pharmaceuticals

    ACAD

    Health Care

    Jan 3, 2025

    S&P SmallCap 600

    Deletion

    Independent Bank Group

    IBTX

    Financials

    For more information about S&P Dow Jones Indices, please visit www.spdji.com 

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com. 

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected] 

    Media Inquiries

    [email protected] 

    Cision View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

    SOURCE S&P Dow Jones Indices

    Get the next $ACAD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $IBTX
    $SPGI
    $SSB

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    10/21/2025$33.00Buy
    Citigroup
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    SouthState Bank Corporation
    $SSB
    9/25/2025$127.00Buy
    TD Cowen
    SouthState Bank Corporation
    $SSB
    7/25/2025$97.00 → $105.00Market Perform
    Hovde Group
    SouthState Bank Corporation
    $SSB
    5/21/2025$110.00Buy
    Jefferies
    ACADIA Pharmaceuticals Inc.
    $ACAD
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    SouthState Bank Corporation
    $SSB
    5/13/2025$106.00Buy
    Truist
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    More analyst ratings

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith G Stacy bought $230,750 worth of shares (2,500 units at $92.30), increasing direct ownership by 7% to 39,546 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    8/4/25 10:55:38 AM ET
    $SSB
    Major Banks
    Finance

    Director Froetscher Janet P bought $324,821 worth of shares (3,338 units at $97.31), increasing direct ownership by 67% to 8,294 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    7/30/25 4:39:55 PM ET
    $SSB
    Major Banks
    Finance

    Director Froetscher Janet P bought $250,018 worth of shares (2,717 units at $92.02), increasing direct ownership by 138% to 4,689 units (SEC Form 4)

    4 - SouthState Corp (0000764038) (Issuer)

    3/11/25 4:10:14 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    S&P Global Introduces S&P Global Energy

    Formerly S&P Global Commodity Insights, this division is the world's leading provider of benchmarks, data, and insights for energy and commodities as part of S&P Global NEW YORK, Nov. 14, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) announced S&P Global Energy as the new name and identity for its Commodity Insights division at the company's 2025 Investor Day.  S&P Global Energy reflects the division's strategic focus on providing world-leading benchmarks, data, and insights that enable its customers to plan, act, and thrive in a rapidly expanding and evolving global energy ecosystem.

    11/14/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global to Present Next Phase of its Growth Strategy and Medium-Term Financial Targets at Investor Day 2025

    Company to Outline its Mission of Advancing Essential Intelligence  Announces New Share Repurchase Program, up to 30 Million Shares NEW YORK, Nov. 13, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI) will present the next phase of its growth strategy at its 2025 Investor Day today in New York. S&P Global President and Chief Executive Officer Martina Cheung and executives will discuss how S&P Global is "advancing essential intelligence" to enable its customers to make more confident decisions and remain a step ahead with S&P Global's industry-leading solutions. S&P Global (NYSE:SP

    11/13/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

    TORONTO, Nov. 12, 2025 /CNW/ - The shareholders of Cenovus Energy Inc. (TSX:CVE) and MEG Energy Corp. (TSX:MEG) have agreed to the terms of a Plan of Arrangement resulting in the combination of the two companies. Each share of MEG Energy will be exchanged for $30.00 in cash or 1.255 shares of Cenovus Energy for each MEG Energy share held, subject to proration such that the aggregate consideration paid to MEG Energy consists of 50% cash and 50% consideration in Cenovus Energy shares. In anticipation of the arrangement closing, MEG Energy will be removed from the S&P/TSX Composite Index prior to the open of trading on November 17, 2025. The shares outstanding of Cenovus Energy will be increas

    11/12/25 5:15:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on ACADIA Pharmaceuticals with a new price target

    Citigroup initiated coverage of ACADIA Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    10/21/25 7:17:42 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Seaport Research Partners initiated coverage on S&P Global with a new price target

    Seaport Research Partners initiated coverage of S&P Global with a rating of Buy and set a new price target of $540.00

    10/1/25 9:39:03 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    TD Cowen initiated coverage on SouthState Bank Corp with a new price target

    TD Cowen initiated coverage of SouthState Bank Corp with a rating of Buy and set a new price target of $127.00

    9/25/25 8:34:15 AM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ACADIA Pharmaceuticals Inc.

    SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/25 8:16:54 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    11/13/25 7:55:11 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    S&P Global Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - S&P Global Inc. (0000064040) (Filer)

    11/10/25 9:00:13 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Leadership Updates

    Live Leadership Updates

    View All

    Sterling Infrastructure Set to Join S&P MidCap 400 and Red Rock Resorts to Join S&P SmallCap 600

    NEW YORK, Nov. 6, 2025 /PRNewswire/ -- Sterling Infrastructure Inc. (NASD: STRL) will replace Light & Wonder Inc. (NASD: LNW) in the S&P MidCap 400, and Red Rock Resorts Inc. (NASD: RRR) will replace Sterling Infrastructure in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, November 13. Light & Wonder is expected to delist from the NASDAQ Stock Exchange on or around that date and intends to keep its primary listing exclusively in Australia. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Nov 13, 2025 S&P MidCap 400 Addition Sterli

    11/6/25 6:20:00 PM ET
    $LNW
    $RRR
    $SPGI
    EDP Services
    Technology
    Hotels/Resorts
    Consumer Discretionary

    Solstice Advance Materials and Qnity Electronics Set to Join S&P 500; Others to Join S&P SmallCap 600

    NEW YORK, Oct. 27, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: Solstice Advance Materials Inc. (NASD: SOLS) will replace CarMax Inc. (NYSE:KMX) in the S&P 500, and CarMax will replace USANA Health Sciences Inc. (NYSE:USNA) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 31. S&P 500 and 100 constituent Honeywell International Inc. (NASD: HON) is spinning off Solstice Advance Materials in a transaction expected to be completed on October 30. Post spin-off, Honeywell International will remain in the S&P 500 and 100. CarMax and USANA Health Sciences no longer represent the large cap and small c

    10/27/25 6:10:00 PM ET
    $CAL
    $DD
    $EMN
    Shoe Manufacturing
    Consumer Discretionary
    Major Chemicals
    Industrials

    BrightSpring Health Services Set to Join S&P SmallCap 600

    NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, October 20. S&P 500 constituent Huntington Bancshares Inc. (NASD: HBAN) is acquiring Veritex Holdings in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 20, 2025 S&P SmallCap 600 Addition BrightSpring Health Services BTSG Health Care October 20, 2025 S&P SmallCap 600 Deletion Veritex H

    10/14/25 6:00:00 PM ET
    $BTSG
    $HBAN
    $SPGI
    Medical/Nursing Services
    Health Care
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daly James M sold $670,983 worth of shares (30,000 units at $22.37), decreasing direct ownership by 88% to 4,041 units (SEC Form 4)

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    11/12/25 6:00:04 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Pou William K Jr was granted 282 shares, increasing direct ownership by 1% to 23,840 units (SEC Form 4)

    4 - SouthState Bank Corp (0000764038) (Issuer)

    11/4/25 4:17:09 PM ET
    $SSB
    Major Banks
    Finance

    Director Page G Ruffner Jr was granted 282 shares, increasing direct ownership by 0.35% to 81,167 units (SEC Form 4)

    4 - SouthState Bank Corp (0000764038) (Issuer)

    11/4/25 4:16:32 PM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SouthState Corporation

    SC 13G/A - SouthState Corp (0000764038) (Subject)

    11/14/24 1:28:29 PM ET
    $SSB
    Major Banks
    Finance

    Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

    SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    11/14/24 6:48:52 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SouthState Corporation

    SC 13G - SouthState Corp (0000764038) (Subject)

    2/14/24 10:04:34 AM ET
    $SSB
    Major Banks
    Finance

    $ACAD
    $IBTX
    $SPGI
    $SSB
    Financials

    Live finance-specific insights

    View All

    S&P Global to Present Next Phase of its Growth Strategy and Medium-Term Financial Targets at Investor Day 2025

    Company to Outline its Mission of Advancing Essential Intelligence  Announces New Share Repurchase Program, up to 30 Million Shares NEW YORK, Nov. 13, 2025 /PRNewswire/ -- S&P Global (NYSE: SPGI) will present the next phase of its growth strategy at its 2025 Investor Day today in New York. S&P Global President and Chief Executive Officer Martina Cheung and executives will discuss how S&P Global is "advancing essential intelligence" to enable its customers to make more confident decisions and remain a step ahead with S&P Global's industry-leading solutions. S&P Global (NYSE:SP

    11/13/25 8:00:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

    - Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID® net product sales guidance to $685 to $695 million - Updating DAYBUE® net product sales guidance to $385 to $400 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2025. "Acadia delivered another strong quarter, generating total revenue of $278.6 million," said Catherine Owen Adams, Chief Executive Officer. "NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by t

    11/5/25 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Reports Third Quarter Results

    NEW YORK, Oct. 30, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today reported third quarter results. The Company's earnings release and supplemental materials are available at http://investor.spglobal.com/Quarterly-Earnings.  Supplemental Information/Conference Call/Webcast Details: The Company's senior management will review the third quarter 2025 earnings results on a conference call scheduled for today, October 30, at 8:30 a.m. EDT. Additional information presented on the conference call, and the Company's supplemental slide content may be found on the Company's Investor Re

    10/30/25 7:18:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance